Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(55)
•••
Comment by frohlir944on Feb 14, 2018 10:18pm
182 Views
Post# 27562425

RE:RE:RE:RE:Biogen shares tumble

RE:RE:RE:RE:Biogen shares tumbleTo keep the Valentine's Day theme going, you want them to kiss and tell.  But the name of the game is secrecy.  None of the big pharma want their competitors knowing that they are getting an advantage ( a huge one in this case).   So regardless of what you want ( pun intended) the first time you will hear about it is when a huge deal, collaboration or buyout is announced.  

By the way, when the news does start to get announced, it sure feels like this thing will break out with a vengeance.  Most of the large stock holders have figured what they are holding and seem very reluctant to sell even though most of us anxious for news and announcements.  Looks like shares are definitely being held for the big run that is now anticipated by most of us.

Regardless, stop being so pessimistic, lots of news will happen before the large deals are announced, starting with monkeys ( hey, maybe one of them needs a valentines date, but be a gentleman, no monkey business ) followed by news about internal programs and many other things like moving to Nasdaq, etc.

in closing, don't worry, be happy!




Bullboard Posts
Dealroom for high-potential pre-IPO opportunities